U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07595965) titled 'Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse' on Jan. 06, 2025.
Brief Summary: To evaluate the safety and tolerability of allogeneic bone marrow-derived mesenchymal stem cells (CE211NS21) in patients with severe anti-aquaporin-4-immunoglobulin G positive neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD) relapse
Study Start Date: Dec. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Neuromyelitis Optica Spectrum Disorder Relapse
Intervention:
BIOLOGICAL: CE211NS21
baseline (D0), 4-week point (Visit 3), and 16-week point (Visit 6) for intrathecal administration o...